



P&T MEETING AGENDA: OCTOBER 13, 2026



COMMONWEALTH OF KENTUCKY
CABINET FOR HEALTH AND FAMILY SERVICES
DEPARTMENT FOR MEDICAID SERVICES
PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE MEETING
NOTE: This special-called meeting will be held virtually via Microsoft Teams webinar.
Tuesday, October 13, 2026
1:00 P.M. to 4:00 P.M. (Eastern)

Smartphone/Web	Dial-In by Phone
Microsoft Teams Join the Meeting Meeting ID: 277 595 346 477 561 Passcode: 6ub2xJ6i Download Teams Join on the web	+1 858-252-2734 (United States) Phone conference ID: 633 689 235#

AGENDA

- I. **Call to Order and Welcome**
- II. **Executive Session (Upon Request)**
- III. **Old Business**
 - a. Approval of April 2026 and July 2026 Meeting Minutes
- IV. **New Business**
 - a. New Products to Market to be Reviewed as Single Products
 - i. Hepcludex® (bulevirtide-gmod) – Non-PDL
 - ii. Xocova® (ensitrelvir) - Anti-Infective – Oral Antivirals, COVID-19: Non-Preferred
 - iii. Lynavoy® (linerixibat) - Gastrointestinal: Bile Salts: Non-Preferred
 - iv. Awiqli® (insulin icodec-abae) - Diabetes: Insulin and Related Agents, Non-Preferred
 - v. Lipfendra® (enlicitide) - Cardiovascular - Lipotropics: Non-Preferred
 - vi. Trutakna™ (atacept-vymj) – Non-PDL
- V. **New Therapeutic Classes**
 - a. Hereditary Angioedema Agents
 - b. Phenylketonuria Agents
- VI. **Therapeutic Classes with Recommended PDL Status Changes**
 - a. Antiparasitics, Topical
 - b. Cytokine & CAM Antagonists
 - c. GI Motility, Chronic





- d. Laxatives & Cathartics
- e. SGLT2 Inhibitors
- f. Ophthalmics, Immunomodulators

VII. Consent Agenda

- a. The following therapeutic classes have no recommended changes and may be voted on as a group under a consent agenda

• Acne Agents, Oral • Acne Agents, Topical • Anti-ulcer Protectants • Antibiotics, Topical • Anticholinergics/Antispasmodics • Antidiarrheals • Antiemetics and Antivertigo Agents • Antifungals, Topical • Antipsoriatics, Oral • Antipsoriatics, Topical • Antivirals, Topical • Bile Salts • H. Pylori Treatment • Histamine II Receptor Blockers • Immunomodulators, Asthma • Immunomodulators, Atopic Dermatitis • Immunosuppressives, Oral • Multiple Sclerosis Agents • Muscular Dystrophy Agents • Ophthalmics, Antibiotic • Ophthalmics, Antibiotic-Steroid Combinations	• Ophthalmics, Antihistamines • Ophthalmics, Anti-Inflammatory Steroids • Ophthalmics, Antivirals • Ophthalmics, Beta Blockers • Ophthalmics, Carbonic Anhydrase Inhibitors • Ophthalmics, Combinations for Glaucoma • Ophthalmics, Glaucoma Agents (Other) • Ophthalmics, Mast Cell Stabilizers • Ophthalmics, Mydriatics • Ophthalmics, NSAIDs • Ophthalmics, Prostaglandin Agonists • Ophthalmics, Sympathomimetics • Otics, Anesthetics and Anti-Inflammatory • Otics, Antibiotics • Proton Pump Inhibitors • Rosacea Agents, Topical • Steroids, Topical • Ulcerative Colitis Agents
---	---

VIII. Adjournment

- a. Schedule of Upcoming Meetings
 - i. 2027 dates TBA





P&T MEETING AGENDA: OCTOBER 13, 2026



To view the most current Preferred Drug List (PDL) and Prior Authorization (PA) criteria, please go to <https://kyportal.medimpact.com/provider-documents/drug-information>.

PUBLIC SPEAKERS: If you would like to speak during the public session, please complete the Speaker Request form located on the Committee Information tab under the Forms section at <https://kyportal.medimpact.com/provider-documents/pt-committee>.

